Global market: about $1.7 trillion, heading for $2.6 trillion
The IQVIA Institute measures global spending on medicines at invoice prices, before off-invoice discounts and rebates. It uses constant US dollars and excludes COVID-19 vaccines and treatments.
| Year | Global medicine spending | Source |
|---|---|---|
| 2019 | about $1.20 trillion | IQVIA, 2025 outlook |
| 2024 | about $1.74 trillion | IQVIA, 2025 outlook |
| 2029 (forecast) | about $2.38 trillion | IQVIA, 2025 outlook |
| 2030 (forecast) | more than $2.6 trillion | IQVIA, 2026 outlook |
IQVIA forecasts 5 to 8% growth a year through 2030, unchanged from last year’s outlook. Evaluate, which counts worldwide prescription drug sales, also expects the market to pass $2 trillion by 2032, growing more than 7% a year from 2025.
Where the growth comes from:
- Therapy areas. Oncology, immunology, diabetes, and obesity drive most of the growth to 2030.
- Countries. The US and 14 other countries account for 76% of global growth to 2030. Pharmerging markets add about $121 billion.
- Patent expiries. These offset part of the growth. IQVIA expects nearly $200 billion in brand losses through 2030, and Evaluate puts more than $500 billion of sales at risk from generics between 2026 and 2032.
By region in 2024:
- The US accounted for about $1 trillion at list prices.
- Europe’s five largest markets spent about $242 billion.
- Japan spent about $68 billion.
US market: $606 billion net in 2025
The US is the largest single market. IQVIA’s US Medicine Use Trends 2026 report:
| Measure | Value |
|---|---|
| Net spending, 2025 | $606 billion, up 10.6% ($58 billion) from $548 billion in 2024 |
| Average net growth, last five years | 9.3% a year |
| Growth from GIP/GLP-1 drugs, 2025 | $14 billion, of which $9.6 billion for obesity and related conditions |
| Patient out-of-pocket costs, 2025 | a record $110 billion |
| Forecast growth to 2030 | 4.5 to 7.5% a year net; 6 to 9% at list prices |
| Net spending in 2030 | about $200 billion higher than 2025, roughly $800 billion (our arithmetic) |
| New medicines launched | 50 to 55 a year on average |
List and net are very different numbers. At list prices, US spending was about $1 trillion in 2024. Rebates and other concessions offset about 46% of invoice value, which is why net manufacturer sales were about $487 billion that year.
Growth is slowing. Patent expiries and policy measures, such as the Medicare Part D out-of-pocket cap, offset part of the volume growth. Medicare out-of-pocket costs fell 2.2% in 2025 after the cap took effect.
Segments and leaders
Therapy areas. These figures are from IQVIA’s 2025 global outlook:
| Therapy area | Size and outlook |
|---|---|
| Oncology | $252 billion in 2024, forecast $441 billion in 2029; the largest area |
| Obesity | grows by about $50.7 billion from 2025 to 2029, at 23 to 26% a year |
| Immunology | grows by about $49 billion to 2029, slowing to 3.5 to 6.5% a year |
| Diabetes | US net growth slows to 1 to 4% a year |
The GLP-1 era. Lilly’s tirzepatide brands made $36.5 billion in 2025 (Mounjaro $23 billion, Zepbound $13.5 billion), passing Merck’s Keytruda. Evaluate forecasts tirzepatide at more than $70 billion by 2032, which would make it “the biggest drug ever.”
Largest companies by 2025 revenue (PharmaCompass):
| Rank | Company | 2025 revenue |
|---|---|---|
| 1 | Eli Lilly | $65.2 billion (+45%) |
| 2 | Pfizer | $62.6 billion |
| 3 | Roche | $62.1 billion |
| 4 | AbbVie | $61.2 billion |
China’s growing role. China accounted for nearly a third of large pharma in-licensing deals with upfront payments of $50 million or more in 2024, according to IQVIA.
Why market size estimates differ
- List or net. US spending was about $1 trillion at list prices in 2024, but about half that after rebates.
- What counts as “net”. IQVIA’s two reports give different 2024 US figures: $548 billion (net spending) and $487 billion (net manufacturer sales). The measures differ, so do not mix them.
- Scope. Some figures cover all medicines, including generics. Others, like Evaluate’s, count prescription drug sales only. IQVIA excludes COVID-19 products.
- Currency. IQVIA uses constant dollars, so its numbers are not directly comparable with company revenue in current dollars.
- Commercial reports. Many market research sites publish very different totals without stating their method. Treat them with care.
Using market data in AI and RAG
- Store each figure with its measure (list, net, invoice, or sales), currency basis, scope, and year.
- Index primary reports (IQVIA, Evaluate, company annual reports) rather than secondhand summaries.
- Keep forecasts separate from actuals, with the forecast date.
- Refresh annually. IQVIA’s global outlook is published early in the year, its US report in spring, and Evaluate’s in June.
Common mistakes
- Comparing a list-price total with a net figure.
- Adding company revenues to estimate market size, which double-counts some sales and misses others.
- Quoting a forecast without its date.
- Using commercial research figures with no method stated.
Checklist
- Measure and price basis recorded for each figure
- Primary sources indexed
- Forecasts dated and labeled
- Annual refresh scheduled
How AskDona helps
AskDona checks the market figures in your business plans, investor decks, and launch forecasts against the reports you load. It shows which source and measure each number comes from, and flags any that are mixed or have no source.
Run a sample market-size evidence check
AskDona shows the evidence; your strategy and finance teams decide.
Editor’s note. This article is general information, not investment advice. Figures come from IQVIA, Evaluate, and PharmaCompass as of their publication dates. Forecasts are those organizations’ own.
FAQ
How big is the global pharma market? About $1.74 trillion in 2024 at invoice prices, according to IQVIA. IQVIA expects more than $2.6 trillion by 2030.
How big is the US market? $606 billion in net spending in 2025, up 10.6%.
How fast will it grow? Globally 5 to 8% a year to 2030. In the US, 4.5 to 7.5% net.
What is driving growth? Oncology, immunology, diabetes, and obesity, led by GLP-1 drugs.
References
All pages opened and checked by October 30, 2026.
| Source | What it supports |
|---|---|
| IQVIA: Global Medicine Use Trends 2026 | $2.6T by 2030, growth drivers, regions |
| IQVIA: 2026 forecast blog | 5 to 8% growth, rebates offset 46%, patent losses, China deals |
| IQVIA: Global Use of Medicines 2025 webinar (PDF) | 2019, 2024, 2029 totals; regions; therapy areas |
| IQVIA: U.S. Medicine Use Trends 2026 | $606B net, growth, out-of-pocket, forecast |
| Evaluate: 2026 World Preview | $2T by 2032, $500B patent risk, tirzepatide |
| PharmaCompass: Top companies and drugs 2025 | Company revenue, tirzepatide sales |